{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:41Z","timestamp":1790419421939,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":2220,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and bone mineral density (BMD) T-score \u2264\u20131.5. Patients were treated with either s.c. daily teriparatide 20\u2009\u03bcg or oral weekly risedronate 35\u2009mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and nonvertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate. Here we present the prospectively planned subgroup analyses of fracture data across subgroups, which were predefined by the following baseline characteristics: age, number and severity of prevalent VFx, prevalent nonvertebral fractures (NVFx), glucocorticoid use, prior osteoporosis drugs, recent bisphosphonate use, clinical VFx in the year before study entry, and baseline BMD. Heterogeneity of the treatment effect on the primary endpoint (new VFx), and the four key secondary endpoints (including clinical fractures and NVFFx) were investigated by logistic and Cox proportional hazards regression models. A total of 1360 women were randomized and treated (680 per group). Mean age was 72.1 years, mean (SD) number of prevalent VFx was 2.7 (2.1), 55.4% had a BMD T-score &amp;lt;\u20132.5, 36.5% had a recent clinical VFx, 28.3% had a prior major NVFx, 43.2% were osteoporosis drug-na\u00efve, 39.3% were recent bisphosphonate users, and 9.3% were taking glucocorticoids at a prednisone-equivalent dose of &amp;gt;5\u2009mg\/d. For most fracture endpoints, the risk reduction of teriparatide versus risedronate did not significantly differ in any of the subgroups analyzed (treatment-by-subgroup interaction p\u2009&amp;gt;\u20090.1), with most subgroups mirroring results from the total study population. In conclusion, in postmenopausal women with severe osteoporosis, the antifracture efficacy of teriparatide compared with risedronate was consistent in a wide range of patient settings, including treatment-na\u00efve and previously treated patients. \u00a9 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.3384","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T07:27:39Z","timestamp":1515828459000},"page":"783-794","source":"Crossref","is-referenced-by-count":107,"title":["Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial"],"prefix":"10.1093","volume":"33","author":[{"given":"Piet","family":"Geusens","sequence":"first","affiliation":[{"name":"Maastricht University Medical CenterMaastrichtThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[{"name":"Lilly Research Center EuropeMadridSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Kendler","sequence":"additional","affiliation":[{"name":"University of British ColumbiaVancouverCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A","family":"Russo","sequence":"additional","affiliation":[{"name":"CCBR Brasil Centro de Analises e Pesquisas Cl\u00ednicasRio de JaneiroBrazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano AF","family":"Zerbini","sequence":"additional","affiliation":[{"name":"Centro Paulista de Investiga\u00e7ao Cl\u00ednicaSao PauloBrazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[{"name":"\u201cSapienza\u201d Rome UniversityRomeItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Body","sequence":"additional","affiliation":[{"name":"CHU BrugmannULBBrusselsBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[{"name":"Regional Hospital of Orl\u00e9ansOrl\u00e9ansFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Greenspan","sequence":"additional","affiliation":[{"name":"Osteoporosis CenterUniversity of PittsburghPittsburghPAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bagur","sequence":"additional","affiliation":[{"name":"Centro de Osteopat\u00edas ComlitBuenos AiresArgentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J","family":"Stepan","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology and Faculty of Medicine 1Charles UniversityPragueCzech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Semmelweis University Medical SchoolBudapestHungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Casado","sequence":"additional","affiliation":[{"name":"University Hospital Parc Taul\u00ed Sabadell (UAB)BarcelonaSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Moericke","sequence":"additional","affiliation":[{"name":"Institut Pr\u00e4ventive Medizin & Klinische ForschungMagdeburgGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"L\u00f3pez-Romero","sequence":"additional","affiliation":[{"name":"Lilly Research Center EuropeMadridSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and DiabetesMedical University of GrazGrazAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"2024021014344774700_jbmr3384-bib-0001","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"2024021014344774700_jbmr3384-bib-0002","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"2024021014344774700_jbmr3384-bib-0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024021014344774700_jbmr3384-bib-0004","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024021014344774700_jbmr3384-bib-0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"2024021014344774700_jbmr3384-bib-0006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"20","key":"2024021014344774700_jbmr3384-bib-0007","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.298.20.2389","article-title":"Factors associated with 5-year risk of hip fracture in postmenopausal women","volume":"298","author":"Robbins","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"2024021014344774700_jbmr3384-bib-0008","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-008-0588-0","article-title":"Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks","volume":"19","author":"Nguyen","year":"2008","journal-title":"Osteoporos Int"},{"issue":"22","key":"2024021014344774700_jbmr3384-bib-0009","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","article-title":"Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial","volume":"157","author":"Ensrud","year":"1997","journal-title":"Arch Intern Med"},{"issue":"9","key":"2024021014344774700_jbmr3384-bib-0010","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024021014344774700_jbmr3384-bib-0011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014344774700_jbmr3384-bib-0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014344774700_jbmr3384-bib-0013","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024021014344774700_jbmr3384-bib-0014"},{"issue":"1","key":"2024021014344774700_jbmr3384-bib-0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014344774700_jbmr3384-bib-0016","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024021014344774700_jbmr3384-bib-0017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024021014344774700_jbmr3384-bib-0018","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014344774700_jbmr3384-bib-0019","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024021014344774700_jbmr3384-bib-0020","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2024021014344774700_jbmr3384-bib-0021","first-page":"31613","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"6736","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"2024021014344774700_jbmr3384-bib-0022","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"2024021014344774700_jbmr3384-bib-0023","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"issue":"20","key":"2024021014344774700_jbmr3384-bib-0024","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"9041","key":"2024021014344774700_jbmr3384-bib-0025","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"18","key":"2024021014344774700_jbmr3384-bib-0026","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/5\/783\/56653204\/jbmr3384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/5\/783\/56653204\/jbmr3384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:01:05Z","timestamp":1710327665000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/5\/783-794\/7605685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,1,12]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3384","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732451030.793549515","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.732451030.793584755","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5,1]]},"published":{"date-parts":[[2018,1,12]]}}}